Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal women: a cross-sectional comparison study by AlAwlaqi, Ahmed & Hammadeh, Mohamed
Menopause - The Journal of The North American Menopause Society
 
Examining the relationship between Hormone therapy(HT) and dry-eye syndrome in
post-menopausal women- A cross-sectional comparison study
--Manuscript Draft--
 
Manuscript Number: MENO-D-15-00168R3
Full Title: Examining the relationship between Hormone therapy(HT) and dry-eye syndrome in
post-menopausal women- A cross-sectional comparison study
Article Type: Original Study
Keywords: Key Words: Dry-eye syndrome;  Hormone therapy;  Postmenopausal women
Corresponding Author: Mohamad Hammadeh, PhD
Universitat des Saarlandes
Homburg/Saar, Saarland GERMANY
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Universitat des Saarlandes
Corresponding Author's Secondary
Institution:
First Author: Mohamad Hammadeh, Prof. Dr. Dr.
First Author Secondary Information:
Order of Authors: Mohamad Hammadeh, Prof. Dr. Dr.
Ahmed AlAwlaqi, MBBS, MSc
Order of Authors Secondary Information:
Manuscript Region of Origin: GERMANY
Abstract: Objective: To examine the relationship between hormone therapy (HT) and dry-eye
syndrome (DES) in post-menopausal women.
Methods: A cross-sectional study was performed on 360 postmenopausal women.
They were grouped into two groups. Group 1 was the control (n=189) without DES
symptoms and did not receive HT treatment. Group 2 (n=177) women with DES
symptoms. Group.2 was randomly grouped into two categories. Group 2A (n=90) that
received estrogen-only HT, and Group 2B (n= 87) who treated with a combination of
estrogen and progesterone HT. The severity of symptom levels was determined using
the OSDI index levels that identify the extent of the relationship between sex hormones
and DES. A further comparison of the severity symptoms among women under HT and
those not under HT was used to establish the relationship between HT and DES in
post-menopausal women.
Results: i) a significant variation in the severity levels of DES across women not under
HT and those who under HT (G2A) and HT (G2B) [F(2, 357)= 974.186, p=.000], ii) a
significant variation in the severity levels of DES  based on dosage levels (<1 mg/day
and >1 mg/day) across women under HT (G2A) and HT (G2B) [F(2, 357)= 302.513,
p=.000]; and iii) a significant variation in the severity levels of DES based on duration
levels 12, 36 and 48 months) across women under HT (G2A) and HT (G2B) [F(3,
356)= 218.266, p=.000].
Conclusion: The current study findings have negated the previous assumption that HT
use contributes to a reduction in DED symptoms among postmenopausal women.
Instead, prolonged HT use appears to increase the risk of DED.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
  
Cover letter 
Dear Mrs. Susan Keefe (assistant Editor)   
Menopause – The Journal of the North American Menopause Society  
We wish to thank you for your interest in our manuscript entitled “Examining 
the relationship between hormone (HT) and dry-eye syndrome in post- 
menopausal women- A cross-sectional comparison study” 
We have done the change according to your suggestion On the figure and 
Tables the word Oestrogen has been changed to Estrogen. 
Hormone replacement therapy (HRT) has been changed to Hormone 
therapy (HT). 
Besides a short summary about the article for the journal table of content 
has been written.  
Thank you very much in advance for your help and guidance 
 
Prof. Dr. ME. Hammadeh 
 
Cover letter
  
 
Response to the Reviewers 
 
Dear Mrs. Susan Keefe (assistant Editor)   
Menopause – The Journal of the North American Menopause Society  
We wish to thank you for your interest in our manuscript entitled “Examining 
the relationship between hormone (HT) and dry-eye syndrome in post- 
menopausal women- A cross-sectional comparison study” 
We have done the change according to your suggestion On the figure and 
Tables the word Oestrogen has been changed to Estrogen. 
Hormone replacement therapy (HRT) has been changed to Hormone 
therapy (HT). 
Besides a short summary about the article for the journal table of content 
has been written.  
Paper Summary 
Hormone therapy has gained popularity as a ministration method for menopause-related 
complaints. However, its potential to increase the risk of dry-eye syndrome (DES) requires 
further investigation. Findings from the current cross-sectional research suggest that HT is 
not a protective factor against the severity of DES in postmenopausal women. As such, the 
findings from the current study should be used to educate healthcare providers and 
postmenopausal women with DES regarding the credibility of HT. Further research is 
needed to develop solutions regarding the risks of HT or to develop more effective 
treatments related to menopause. 
Thank you very much in advance for your help and guidance 
 
Prof. Dr. ME. Hammadeh 
 
 
Response to Reviewers
  
 
 
 
 
 
Examining the relationship between hormone therapy (HT) and dry-eye 
syndrome in postmenopausal women:  A cross-sectional comparison study 
 
 Running Title:  Hormone therapy and dry-eye syndrome 
 
 Ahmed AlAwlaqi MBBS, MSc, Mohamed Hammadeh, Ph.D. 
 
 Department of obstetrics & Gynecology; University of Saarland; 66421 Homburg/Saar, 
 Germany 
 
 Funding: No fund obtained for this study 
 
 Conflicts of interests: The authors declare that they have no conflicts of interests 
 
 Correspondence: 
 Prof. Dr. Dr. ME Hammadeh 
 Dept. of Obstetrics and Gynecology 
 University of Saarland 
 66421 Homburg Saar 
 Tel: 004968411628117 
 Fax:004968411628443 
 Office E-Mail: mohamad.eid.hammadeh@uks.eu 
 Second E.mail: mehammadeh@yahoo.de 
 
 
 
 
 
 
 
 
 
Manuscript (All Manuscript Text Pages, including Title Page, References and Figure Legends)
  
Objective:  To  examine  the  relationship  between  hormone  therapy  (HT)  and  dry-eye 
syndrome (DES) in post-menopausal women. 
 
Methods: A cross-sectional study was performed on 360 postmenopausal women. They 
were grouped into  two  groups.  Group 1  was  the  control  (n=189)  without  DES 
symptoms and did not receive HT treatment. Group 2 (n=177) women with DES 
symptoms. Group.2 was randomly grouped into two categories. Group 2A (n=90) that 
received estrogen-only HT, and Group 2B (n= 87) who treated with a combination of 
estrogen and progesterone HT. The severity of symptom levels was determined using the 
OSDI index levels that identify the extent of the relationship between sex hormones and 
DES.  A  further  comparison  of  t h e  severity  symptoms  among  women  under  HT  and 
those not  under  HT was used to establish the relationship between HT and DES in post- 
menopausal women. 
 
Results: i) a significant variation in the severity levels of DES across women not under HT 
and those who under HT (G2A) and HT (G2B) [F(2, 357)= 974.186, p=.000], ii) a significant 
variation in the severity levels of DES  based on dosage levels (<1 mg/day  and >1 mg/day) 
across women under HT (G2A) and  HT  (G2B)  [F(2, 357)= 302.513,  p=.000]; and iii) a 
significant variation in the severity levels of DES based on duration levels 12, 36 and 48 
months) across women under HT (G2A) and HT (G2B) [F(3, 356)= 218.266, p=.000]. 
Conclusion: The current study findings have negated the previous assumption that HT use 
contributes to a reduction in DED symptoms among postmenopausal women. Instead, 
prolonged HT use appear to increase the risk of DED.  
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 Introduction 
Menopause is a natural decline in reproductive hormones when a woman reaches her 40s or 
50s.1  This phase marks the end of a woman's reproductive years because a woman’s body 
slowly produces less of the hormones estrogen and progesterone2.  According to Moulton et al. 
57 More than 30 million women in the United States are now in or past menopause, and another 
6 million women will enter menopause during the next decade. Menopause and its 
corresponding transitional phases impact the physical and psychological subsistence of women, 
and studies on the symptoms and effects of menopause identify adverse effects on women’s 
physical performance3  and occupational performance4  reduced health5  with diseases such as 
cardiovascular6,7, and osteoporosis8,9, along with depression10,11,12 and loss of quality of 
life.13,14,15,16    Dry-eye syndrome (DES) is another risk factor associated with menopause17,18 
and DES or Kerato Conjunctivitis Sicca (KCS) can be defined as group of conditions of the 
ocular surface and tears which produce aberrations in the tear film, resulting in perpetual visual 
discomfort and disturbances with eventual potential to damage the ocular surface.19 
 
Characterized  by  clinical  symptoms  such  as  consistent  “ocular  burning,  foreign  body 
sensation,  stinging  sensation,  pain,  photophobia  or  blurred vision20   the  resulting outcome 
exposes the individual to red eyes, pain and eventual fatigue.21  Given the broad range of 
symptoms, the attribution of DES as a “multifactorial ocular disease”19  can be validated in 
this regard and the detrimental impacts of DES on the quality of health 22,23,24,25 and vision 26 
of  the  affected  individuals  compounded  by  various  epidemiological  s t u d i e s   can  be 
indicatively established to outline a crucial claim that, DES has the potential to impair normal 
functioning of individuals. 
 
Apart from environmental, physiological and pathological causes, hormonal changes can also 
be attributed  to DES  20. A  number  of  studies  have  identified  a relationship between sex 
hormones and  DES  27-32  especially  in  postmenopausal  women.  In  a  study  conducted  by 
Jones-Jordan   and   Nichols,   it   was   revealed   that   nearly   63%   of   the   evaluated   939 
postmenopausal women suffered from  eye  dryness.   Such findings further emphasize the 
need for identifying the extent of  the relationship between sex hormones and dry eye, given: i) 
the common presence of DES in  the population34   and  ii) considering that post-menopausal 
women experience severe hormonal changes, given the aberrations in the endocrine systems 
of women 35  and subject themselves to various treatments to maintain a certain balance in 
their daily lives. One such treatment that has gained wide popularity is Hormone therapy (HT). 
 
HT refers to a regular administration of hormones-estrogen and progesterone to post- 
menopausal women to minimize the physical and psychological effects of menopause36. HT 
has  gained  popularity  as  a  ministration  method  for  menopause  related complaints  36  and 
previous  studies  popularized   cardiovascular   improvement  and  bone  density  and   lipid 
metabolism improvement as other beneficial effects of HT36. However, critics have expressed 
their concern about  the  detrimental  effects  of  HT.37-39  For example, potential relationships 
between HT and cancer risk and HT and DES have been established40,41  Literature on the 
relationship  between HT and DES reflect both the advantages and risks of HT on dry eye. 
Certain studies indicate the risks of HT and claim that HT with estrogen and estrogen with 
progesterone has increased risks of DES in women41. However, certain other studies42,43 
reflect otherwise. Despite the various study findings, the relationship between DES and HT is 
still a debatable subject because a gap still exists in this field. The current study aims to 
bridge  the  gap  and  adds  to  the existing literature  by  examining  the  relationship  between 
hormone therapy  (HT)  and  dry-eye  syndrome  in  postmenopausal  women through a 
comprehensive a cross-sectional comparison study. 
 
 
 
Hypothesis: There is a correlation between HT use and a reduction in DES severity in 
postmenopausal women. 
 
 Materials and Methods: 
 
A cross-sectional study was performed on 360 postmenopausal women (aged 49 years 
and above) for a period of 2 years based on a database of 2,000 postmenopausal women 
who had visited the clinics in the past 4 years. 
 
Data of the participants was collected from 30 Gynaecological clinics with the majority 
of the information obtained from Tawam Hospital in affiliation with John Hopkins 
International Clinic (Al Ain) (n=93), Germany Homburg Saar (n=62), SKMC Sheikh 
Khalifa Hospital managed by Cleveland Clinic (Abu Dhabi) (n= 53), Al Ain Hosp ital 
(Al  Ain  City)  (n=37)  The  rest  of the data from  (n=115)  participants  came from  the 
remaining 26 clinics. Each clinic was asked to provide 14 post- menopausal women (7 not 
under HT and 4 under estrogen alone and 4 under estrogen and progesterone) suffering from 
DES, with an estimate of 360 sample size. 
 
The participants were grouped into two groups. Group 1 was the control composed of 
(n=189) subjects without DES symptoms and did not receive HT treatment. Group 2 
included  (n=177) women  with  DES symptoms that  were randomly grouped into two 
categories. Group 2A included 90 subjects that received estrogen-only HT, and Group 
2B consisted of 87 subjects treated with a combination of estrogen and progesterone 
HT. The severity of symptom levels was determined using the OSDI index levels of normal, 
mild, moderate and severe that identifies the extent of the relationship between sex hormones 
and DES. A further comparison of t h e  severity symptoms among women under HT and 
those not  under  HT was used to establish the relationship between HT and DES in post- 
menopausal women. 
 
To ascertain the presence of DES in women, two questions pertinent to frequency of eyes 
getting  dried  or irritated  and  clinical  diagnosis  of  DES,  based  on  studies  concerning 
hormone   therapy  and   dry-eye   conducted   by  Schaumberg   et   al.,41.   Only women  that  
complained  of ‘constant’ feeling  of dryness and  feeling of dryness  often or sometimes 
were asked to take a survey based on IDEEL dry-eye symptoms bother module. Subjects with 
DES-inducing conditions such as diabetes, hypertension, depression, rheumatoid arthritis,  
users of systematic or topical medications, and  contact lens wear were excluded from 
the study. 
 
Choosing survey method as the primary data collection method for data collection was based 
on the understanding that assessing the presence of relationship between symptoms and signs 
of DES remains as an issue 19,27,33,44-48 which questions the reliability of the tests. Even if the 
clinical tests achieve to establish a relationship, assessing the severity of the DES is very 
poor44,50-54. Thus, a study that practically applied the IDEEL survey developed by Abetz et 
al55. The development and  validation of the impact of dry eye on everyday life (IDEEL) 
questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of 
dry eye on patients to present a cohort assessment of the symptoms of DES was considered as 
an  apt  contextual  requirement.  No  doubt,  the  symptoms  presented  in  the  Ocular  Surface 
Disease Index (OSDI)56  assess the presence of DES; however, the detailed list of symptoms 
in the IDEEL survey ensures the comprehensiveness and validity of the current study. 
 
A combination of IDEEL survey for  collecting data (demographical and DES symptoms) 
from the postmenopausal women and use of OSDI index to measure the severity levels of 
DES in postmenopausal women under HT and not under HT proved as a unique contribution 
to the literature. A novel aspect in the field, each of the 360 participants’ OSDI score was 
calculated on a scale of 0-100. The OSDI score was calculated based on the OSDI formula: 
OSDI score = (sum of scores) * 25 / (number of questions answered).
 With a range of severity levels based on percentile deviation, the OSDI scores of the 
postmenopausal women and their respective groups were assorted under mild (<25), moderate 
(in and around 50) and severe levels (>75). The obtained results were further subjected to 
statistical analysis using SPSS software, where descriptive statistics, ANOVA and post hoc 
analysis using Welch and Brown-Forsythe tests were conducted
 Results 
 
An overview of the collected demographic data establishes a direct relationship between HT 
usage, and demographic and social characteristics (Tab. 1). HT usage  is prevalent among 
younger women  with  greater educational  qualification  and income. As hypothesized,  the 
frequency of eye examinations of  post-menopausal  women under HT was higher than women 
not under HT in the past 2 years irrespective of the duration and dosage of HT. Only 8.9% of 
the respondents belonged to normal range of the OSDI index (below 11.5 score based on 
OSDI index)56, establishing the presence of mild, moderate or severe symptoms of DES among 
the remaining participants. 
 
Post hoc comparisons indicated that mean score for postmenopausal women not under HT 
(M = 22.76, SD = 11.92765) was significantly different than postmenopausal women under 
HT  estrogen  only (M  =  92.52,  SD  =  12.93711)  and  postmenopausal women  under  HT 
estrogen  and  progesterone  (M  =  50.89,  SD  =  12.44588).  On  similar  lines,  post  hoc 
comparisons also indicated that mean score for postmenopausal women with <1mg/day HT 
dosage (M = 69.032, SD = 25.48232) was significantly different than postmenopausal women 
>1mg/day HT dosage (M = 74.082, SD = 23.56768). Post hoc comparisons also indicated 
that mean score for postmenopausal women with 12 months HT treatment (M = 61.23, SD 
=25.93619)  was  significantly  different  than  postmenopausal  women  with  36  months  HT 
treatment (M  = 77.641, SD = 24.24393) and  48 months  HT treatment (M  = 75.116, SD 
=21.95054). 
 
Welch and Brown-Forsythe tests were conducted to indicate the significance levels of any 
non-normal  distributed data.   The combined results of the three ANOVA  tests and their 
respective descriptive statistics is indicated in the below table. Analysis of variance (ANOVA) 
showed: i) significant variation in the severity levels of DES across women not under HT, 
under HT (estrogen alone) and HT (estrogen and progesterone) [F(2, 357)= 974.186, p=.000] 
(Tab. 2; Fig. 1). Users of HT include only current users with the most recent assigned therapy. 
Variation in the severity levels of DES across the three categories of HT were significant in 
accordance with the severity definition of mild, moderate and severe (p<0.001). 
 
Besides, a significant variation in the severity levels of DES based on dosage levels (<1 mg/day 
and  >1  mg/day)  across  women  under  HT  (estrogen  alone)  and  HT  (estrogen  and 
progesterone) [F(2, 357)= 302.513, p=.000] (Tab. 3 Fig. 2). Dosage levels include only current 
users with the most recent dosage levels. Variation in the severity levels of DES across the two 
categories of HT were significant in accordance with the dosage definition of <1 mg/day and 
>1 mg/day (p<0.001). 
 
Moreover, a significant variation in the severity levels of DES based on duration levels 12, 36 
and  48  months)  across  women  under  HT  (estrogen  alone)  and  HT  (estrogen  and 
progesterone) [F (3, 356) = 218.266, p=.000] (Tab 4; Fig. 3). Duration of HT includes only 
current users under HT for ≤48 months. Variation in the severity levels of DES across the two 
categories of HT were significant in accordance with the duration definition of 12, 36 and 48 
months (p=0.000).
 DISCUSSION 
 
Postmenopausal women undergo severe physical,  psychological and physiological  changes 
that require certain treatments to accomplish daily functionalities. While hormone therapy  
(HT)  has  gained  popularity  as  a  ministration  method  for  menopause  related complaints,  
its  potential  to  increase  the  risk  of  dry-eye  syndrome  (DES)  requires further investigation. 
DES has the potential to impair normal functioning of individuals, and study validating the 
relationship between sex hormones and dry eye, especially in postmenopausal women and HT 
and DES in postmenopausal women is essential to add to the literature in obstetrics and 
gynaecology fields regarding the relationship between DES and HT. 
 
This present cross-sectional  comparison  study  practically  applied the IDEEL  survey and 
OSDI analytical method to examine the relationship between hormone therapy (HT) and dry-
eye syndrome in post-menopausal women. Unique contribution to literature is the presence 
of obvious increased eye examinations of post-menopausal women under HT in the past 2 
years irrespective of the duration and dosage of HT. The results of the present study showed 
the presence of a significant relationship between sex hormones and DES with mild, moderate 
or severe symptom in postmenopausal women (Tab 3; Fig.   2). Also these results are in  
accordance  with  various  studies20,   27-34    that have scientifically validated the relationship 
between sex hormones and DES. 
 
Besides, the statistical analysis showed significant variation in severity levels of DES clearly 
indicated that women under HT estrogen only were at higher risk than women under HT 
estrogen and progesterone. The presence of mild levels of DES among women not under 
HT clearly indicates that women under HT need to reassesses their acceptance of menopausal 
treatments  to  avoid  ocular  surface  discomforts. This is in line with studies that indicate 
possible relationship between HT and increased risks of DED, especially for women under 
estrogen only treatment41 and refutes the studies that fail to establish relationship between HT 
and DED.42,43 One of the possible explanation for lack of this correlation in the current study 
is that Schaumberg et al41  base their conclusions on the patient’s symptoms and the self - 
reported clinical diagnosis. In the current study, all the patients were subjected to ocular 
exam for dry eye syndrome by the same clinician. Such an approach reduced the selection 
bias and standardized the dry eye diagnosis criteria. According to Schaumberg et al41 another 
possible variation can be explained by the lack of relationship between HT and reduced dry 
eye symptoms may be attributed to genetic makeup of the study subjects. 
 
Study Limitation 
 
The study has a number of potential limitations. First, the study did not control for the various 
DES  symptoms  despite  the  fact  that  the signs  are  not  necessarily unique to  DES.  Other 
conditions also feature DES-like symptoms, such as conjunctivochalasis, recurrent corneal 
erosions, various neuropathies, epithelial basement membrane dystrophy, and Parkinson's 
disease. Second, the paper is further limited by the fact that the OSDI was the key component 
of the study. One limitation of the OSDI is that it only includes some dry eye symptoms such 
as grittiness, sensitivity to light, and pain but does not include other symptoms such as foreign 
body sensation and tearing.58,59 14 It also only discusses some of the effects of DED on vision- 
related functioning; therefore, it may not capture the entire effect of DED on a patient’s daily 
living.58  In addition, OSDI responses are limited to measures of frequency (rather than to 
frequency and severity).60 A second limitation of the OSDI that can affect the interpretation of 
the results is that the effort required to complete and score the scale, which may consume 
valuable clinic time in a practice.61 
 
Another limitation is that there was no control made for the different dry eye diseases or types, 
environmental stress, climate, diurnal variations, and the individual lifestyle changes and 
patterns. Moreover, scholars58,60 continue to point out that the DED severity measurements 
 widely differ, stressing the importance of averaging the results three times to obtain a more 
reliable figure. The current study also performed a single eye osmolality test on each eye at the 
time of the visit. As such, future studies undertaking three successful measurements on each eye 
may yield more reliable study findings. Lastly, the study did not include the epidemiological 
aspect across different ethnic or racial backgrounds to assess its possible effect on the DED 
severity among women receiving HT during the treatment duration. 
 
 
Conclusion: The research findings have failed to establish the previous assumption that HT use 
contributes to a reduction in DED symptoms among postmenopausal women. Rather, the use of 
HT among postmenopausal women for a prolonged period of time appear to increase the risk of 
DED.  
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 Legend for the figure 
Figure 1.  Illustrate  the  severity  levels  of  DES  among  the  study  participants  and  
their relationship to HT treatment. 
Subjects  that  were  administered  with  estrogen-only  HT  appear  to  have  a  higher  OSDI 
compared to the subjects using a HT combination of estrogen and progesterone HT. 
 
 
 
Figure 2: Presents the severity levels which appear to be higher in subjects using more than 1 
mg/day of estrogen only HT, than subjects taking the same dosage of estrogen and 
progesterone HT. In addition, the severity is higher in subjects taking less than 1 mg/day 
estrogen only HT than in those taking the same dosage of estrogen and progesterone. 
 
Figure 3: shows that women who received estrogen only HT in this duration appears to show 
high severity levels than the other study subjects. Prolonged use of the HT appears to increase 
the severity levels of the DES in postmenopausal women.
  
  
 
 
 
 
 
 
Table 1: Demographic data showing HT users and non-users in the study 
 
 
 
 Dry eye Non-Dry eye Total p value 
Age (years)     
Mean (SD)   55.89±11.89  
Education, n (%)    0.870 
Primary 10 (2.8) 15(4.2) 25 (7.0)  
Intermediate 9 (2.5) 13(3.6) 22 (6.1) 
Secondary 14 (3.9) 18(5.0) 32 (8.9) 
Graduate 114 (31.7) 109 (30.2) 223 (61.9) 
Post Grad 30 (8.3) 28(7.8) 58 (16.1) 
HT, n (%)    0.003 
Group 1 HT (-) 0 183 (50.8) 183(50.8)  
Group 2A HT (+) 
Estrogen-only 
90(25.0) 0 90(25.0) 
Group 2B HT (+) 
Estrogen/progesterone 
87(24.2) 0 87(24.2) 
 
 
A total of 177 subjects received HT treatment, while the control group of 183 subjects did not 
receive any HT. The participants aged 49 years and above with a mean age being 55.89±11.89 
years old. The graduates (61.9%) formed more than half of the study population followed by 
post-graduates (16.1%), secondary (8.9%), Primary (7%) and intermediate (6.1%) school 
leavers, Table 1.
Table
 Table 2: A comparison of the severity of DED between HT users after a 48 month treatment 
period. There was a statistically significant difference between Group 2A and Group 2B. 
Estrogen and progesterone HT users (Group 2B) showed significant reduction in the number 
of patients with DED symptoms than estrogen-only users (Group 2A) (p=0.001).  
 
  Tear Osmolality 
(mOsm/L) 
Ocular Surface 
Disease Index 
Symptom Assessment in Dry 
Eye 
Severity Frequency 
N Mean± SD Median (25%, 
75%) 
Median 
(25%, 75%) 
Median (25%, 
75%) 
All (n) 177 302.5 ± 14.3 4.6 (0.1, 10.3) 7.1 (1.1,19.1) 12.1 (4.0, 26.0) 
HT use (12 months) 
Group 2A 90 302.7 ± 14.3 5.4 (1.2, 14.7) 11.0 
(2.0,28.0) 
17.5 (7.0, 29.0) 
Group 2B 87 301.2 ± 13.7 4.3 (1.0, 7.6) 11.0 
(1.0,12.0) 
17.1 (1.0, 22.0) 
Group 1 183 300.1 ± 12.6 4.2 (1.0, 7.3) 2.0 (0.0, 12.0) 6.3 (1.0, 23.0) 
Difference 
95% CI* 
 2.7 [-3.0, 8.3] 1.2 [-2.2, 5.3] 8.0 [2.3, 18] 12.5 [2.3, 19] 
p-value*  0.39 0.27 0.02 0.001 
HT use (36 months) 
Group 2A 90 303.9 ± 16.5 4.7 (1.0, 13.7) 12.7 
(6.3,32.3) 
23.0 (9.3, 32.0) 
Group 2B 87 302.7 ± 12.5 4.6 (1.1, 12.2) 2.1 (0.1, 11.2) 6.1 (1.1, 14.0) 
Group 1 183 299.7 ± 12.3 4.6 (0.0, 8.2)   
Difference 
95% CI* 
 4.3 [-1.7, 9.7] 0.04 [-2.1, 4.2] 10.5 [6, 17] 15.1 [9, 21] 
p-value*  0.16 0.54 0.0001 <0.001 
HT use (48 months) 
Group 2A 90 305.4 ± 17.5 5.3 (2.1, 14.6) 14.0 
(7.0,33.0) 
22.5 
(10.0,40.0) 
Group 2B 87 302.7 ± 16.3 4.7 (0.0, 13.7) 12.1 
(0.0,12.0) 
20.3 
(10.1,35.0) 
Group 1 183 299.9 ± 11.7 3.3 (1.0, 10.6) 6.0 (1.0,11.0) 8.0 (1.1, 21.0) 
Difference 
95% CI* 
 5.7 [-0.02, 11.6] 1.2[-1.3,7.2] 12.1 [7, 29] 25.5 [6.5, 26.1] 
p-value*  0.053 0.37 0.0003 0.003 
 
 
 
There was a statistically significant difference between these two groups. Estrogen and 
progesterone HT users showed significant reduction in the number of patients with DES 
symptoms than estrogen-only users (p=0.001). Besides, there was a significant relationship 
in reduction of DES in HT users and non-users after 48 month treatment period (p=0.003). 
 
 
 
*95% confidence intervals (CI) calculated from the standard error of the difference for tear 
osmolality. 
 
**p-values calculated by t-test for tear osmolality and by Wilcoxon rank sums tests for others
 Table 3: ANOVA test results examining dosage levels of HT administration for 
postmenopausal women. 
 
 N Mean 
 
M±SD 
Standard 
Error 
95% Confidence Interval of P-Value 
Difference in 
dosage levels 
of HT 
administration 
 Lower  
Bound 
Upper Bound 
<1mg/day 71 69.03±25.48 3.02 63.0008 75.064  
*< 0.001 
>1mg/day 106 74.08±23.56 2.281 69.5432 78.6209 
 
 
 
* Values are expressed at 95% confidence interval and are based on separate ANOVA and 
Welch and Brown -Forsythe tests for each outcome 
 
Dosage levels <1 mg/day and > 1mg/day between HT E and HT Estrogen & Progesterone
  
 
 
 
 
Table 4: ANOVA test results examining the variance in the duration of HT 
administration for postmenopausal women 
 
  
N 
 
 
 
M±SD 
 
Standard 
Error 
 
95% Confidence 
Interval of Mean 
 
 
P-Value 
 
Difference in 
duration of 
HT 
administration 
  
 
Lower 
Bound 
 
 
Upper 
Bound 
 
 
12 Months 
 
 
47 
 
 
61.23±25. 
93 
 
 
3.78 
 
 
53.61 
  
 
 
 
 
 
 
 
< 0.001 
 
36 Months 
 
44 
 
77.64±24. 
24 
 
3.65 
 
70.27 
 
 
48 Months 
 
48 
 
75.12±21. 
95 
 
2.36 
 
70.41 
 
 
 
 
 
 
The  severity  levels  of  DES  among  the  study  participants  and  their  relationship  to  HT 
treatment is shown in Figure 1. Subjects that were administered with estrogen-only HT 
appear to have a higher OSDI compared to the subjects using a HT combination of estrogen 
and progesterone HT. 
Dosage levels <1 mg/day and > 1mg/day between HT E and HT E & P; and duration 12,36 
and 48 months between HT E and HT E & P. 
 
* Values are expressed at 95% confidence interval and are based on separate ANOVA and 
Welch and Brown-Forsythe tests for each.
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Figure 1: Severity levels of DES in relation to HT usage in the control and study groups.
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Figure  2:  Severity  levels  of  DES  in  relation  to  HT  dosage  levels  among  360  
Postmenopausal women
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Figure 3: Severity levels of dry-eye syndrome in relation to HT use among 360 post- 
menopausal women
  
